Publikationen in Zusammenarbeit mit Forschern von Christie Hospital NHS Foundation Trust (12)

2022

  1. A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry

    Journal of Thoracic Oncology, Vol. 17, Núm. 5, pp. 661-674

  2. The impact of COVID-19 on oncology professionals—one year on: lessons learned from the ESMO Resilience Task Force survey series

    ESMO Open, Vol. 7, Núm. 1

2021

  1. The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II

    ESMO open, Vol. 6, Núm. 4, pp. 100199

  2. The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration

    ESMO open, Vol. 6, Núm. 2, pp. 100058

2020

  1. Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) – A decision-making analysis amongst European lung cancer experts

    Lung Cancer, Vol. 146, pp. 6-11

  2. Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts

    Radiotherapy and Oncology, Vol. 149, pp. 84-88

2019

  1. Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts

    Radiotherapy and Oncology, Vol. 135, pp. 74-77

  2. Erratum to “Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts” [Radiother. Oncol. 135 (2019) 74–77](S0167814019300775)(10.1016/j.radonc.2019.02.010)

    Radiotherapy and Oncology

  3. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the committee for medicinal products for human use (chmp)

    Annals of Oncology

  4. Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts

    Radiotherapy and Oncology, Vol. 133, pp. 163-166

2018

  1. A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)

    Lung Cancer, Vol. 120, pp. 27-33

2010

  1. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): A phase 4 study

    The Lancet Oncology, Vol. 11, Núm. 8, pp. 733-740